Diagnosis and treatment of hyperhomocysteinemia.

M. E. Keebler, Cyrus V Desouza, V. Fonseca

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Hyperhomocysteinemia has emerged as an important risk factor for cardiovascular disease. However, its place in clinical practice is somewhat unclear, due to the lack of clinical trials documenting the benefit of treatment on reducing cardiovascular events. Vitamin therapy, particularly with folic acid, reduces plasma homocysteine significantly and improves other surrogate markers of cardiovascular risk such as endothelial function. Although a consensus is lacking on the right approach to diagnosis and treatment of this risk factor, we have suggested an algorithm based on data from clinical studies. We are optimistic that such an approach will be helpful for the clinician until clinical trials, with cardiovascular events as endpoints, are completed.

Original languageEnglish (US)
Pages (from-to)54-63
Number of pages10
JournalCurrent atherosclerosis reports
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

Hyperhomocysteinemia
Clinical Trials
Homocysteine
Folic Acid
Vitamins
Cardiovascular Diseases
Biomarkers
Therapeutics
Clinical Studies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Diagnosis and treatment of hyperhomocysteinemia. / Keebler, M. E.; Desouza, Cyrus V; Fonseca, V.

In: Current atherosclerosis reports, Vol. 3, No. 1, 01.01.2001, p. 54-63.

Research output: Contribution to journalReview article

Keebler, M. E. ; Desouza, Cyrus V ; Fonseca, V. / Diagnosis and treatment of hyperhomocysteinemia. In: Current atherosclerosis reports. 2001 ; Vol. 3, No. 1. pp. 54-63.
@article{3cb8fdb0a1b04023af921ecf3c86a496,
title = "Diagnosis and treatment of hyperhomocysteinemia.",
abstract = "Hyperhomocysteinemia has emerged as an important risk factor for cardiovascular disease. However, its place in clinical practice is somewhat unclear, due to the lack of clinical trials documenting the benefit of treatment on reducing cardiovascular events. Vitamin therapy, particularly with folic acid, reduces plasma homocysteine significantly and improves other surrogate markers of cardiovascular risk such as endothelial function. Although a consensus is lacking on the right approach to diagnosis and treatment of this risk factor, we have suggested an algorithm based on data from clinical studies. We are optimistic that such an approach will be helpful for the clinician until clinical trials, with cardiovascular events as endpoints, are completed.",
author = "Keebler, {M. E.} and Desouza, {Cyrus V} and V. Fonseca",
year = "2001",
month = "1",
day = "1",
doi = "10.1007/s11883-001-0011-1",
language = "English (US)",
volume = "3",
pages = "54--63",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Diagnosis and treatment of hyperhomocysteinemia.

AU - Keebler, M. E.

AU - Desouza, Cyrus V

AU - Fonseca, V.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Hyperhomocysteinemia has emerged as an important risk factor for cardiovascular disease. However, its place in clinical practice is somewhat unclear, due to the lack of clinical trials documenting the benefit of treatment on reducing cardiovascular events. Vitamin therapy, particularly with folic acid, reduces plasma homocysteine significantly and improves other surrogate markers of cardiovascular risk such as endothelial function. Although a consensus is lacking on the right approach to diagnosis and treatment of this risk factor, we have suggested an algorithm based on data from clinical studies. We are optimistic that such an approach will be helpful for the clinician until clinical trials, with cardiovascular events as endpoints, are completed.

AB - Hyperhomocysteinemia has emerged as an important risk factor for cardiovascular disease. However, its place in clinical practice is somewhat unclear, due to the lack of clinical trials documenting the benefit of treatment on reducing cardiovascular events. Vitamin therapy, particularly with folic acid, reduces plasma homocysteine significantly and improves other surrogate markers of cardiovascular risk such as endothelial function. Although a consensus is lacking on the right approach to diagnosis and treatment of this risk factor, we have suggested an algorithm based on data from clinical studies. We are optimistic that such an approach will be helpful for the clinician until clinical trials, with cardiovascular events as endpoints, are completed.

UR - http://www.scopus.com/inward/record.url?scp=0035219131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035219131&partnerID=8YFLogxK

U2 - 10.1007/s11883-001-0011-1

DO - 10.1007/s11883-001-0011-1

M3 - Review article

VL - 3

SP - 54

EP - 63

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 1

ER -